Metformin Reverses Key Aging Defect in Skin Pigment Cells

Age-related changes in skin pigmentation — like the light spots that appear on sun-exposed arms and legs in older adults — have long been linked to melanocyte dysfunction, but the earliest molecular triggers have remained poorly understood. This study set out to identify those initiating events and test whether they could be therapeutically targeted.

Using single-cell RNA sequencing and time-course bulk transcriptome analysis on UVB-induced senescent melanocytes, the researchers mapped the sequence of molecular changes that unfold as melanocytes age. They found that autophagy dysregulation is not a downstream consequence of senescence — it is an early driver. Specifically, downregulation of ATG7, a protein essential for the cellular recycling process known as autophagy, emerged as the earliest detectable molecular alteration, preceding the glycolytic reprogramming typically associated with senescent cells.

ATG7 deficiency was confirmed in both lab-aged melanocytes and in skin biopsies from idiopathic guttate hypomelanosis lesions, a common hypopigmentary condition in aging skin. This dual validation strengthens the clinical relevance of the finding. Knockdown and overexpression experiments further confirmed ATG7's causal role in melanocyte senescence.

Metformin treatment proved capable of restoring autophagic flux, upregulating ATG7, reducing oxidative stress, and delaying the senescence phenotype in melanocytes. This adds to the growing body of evidence supporting metformin's pleiotropic anti-aging effects, now extended to skin biology.

Key caveats include the study's reliance on in vitro and ex vivo models, with no clinical trial data yet available. Whether topical or systemic metformin can meaningfully prevent pigmentation disorders in humans remains to be demonstrated in prospective studies.